Alchemab Therapeutics raises £24m Series A extension led by Ono Venture Investment to advance AI-enabled antibody platform

Alchemab identifies naturally occurring protective antibodies using AI and patient data, developing new therapies based on disease resilience rather than traditional target discovery.